The evaluation of efficacy and safety of new Iranian filgrastim brand drug (PDgrastim*) in treatment of leukemic patients neutropenia
- At: 2008 FIP Congress in Basel (Switzerland)
- Type: Poster
- By: SOHREVARDI, Seyed mojtaba (Faculty of pharmacy, Kerman, Iran)
- Co-author(s): Kalantari, Behjat (Faculty of medicine, Kerman, Iran)
Jalali, Seyed pouyan (Faculty of medicine, Kerman, Iran)
The acute leukemias are clonal hematopoietic malignant disease that arise from the malignant transformation of an early hematopoietic stem cell, leukemia occurs in 8 to 10 in 100,000 people. these patients usually suffer than several weeks of neutropenia due to chemotherapy. We decided to evaluate the efficacy and safety of PDgrastim* (The new.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.